Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Ionis ASO Zanvastro for Alexander Disease From Infancy

4 September 2026 · By · Wire by Fusion42

Published

4 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

The US FDA has approved Ionis Pharmaceuticals' antisense oligonucleotide Zanvastro (zilganersen) to treat Alexander disease from infancy through adulthood.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 3 Sep 2026 and 4 Sep 2026.

◆ ◆ The Wire takeaway

You have a new regulatory precedent for launching antisense treatments in rare pediatric diseases in the US. Now is the time to talk to US payers and patient groups to speed market access and uptake.

◆ Coverage

9 sources · first reported 3 Sep 2026 · latest 4 Sep 2026

◆ Topics

Biotechfda-approvalantisense-oligonucleotidesrare-diseasealexander-diseasepharma